Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma

Arthritis and Rheumatism

Volumn 58, Issue 5, 2008, Pages 1465-1474

  Duan, Hangjun ^a   Fleming, Jo ^a   Pritchard, David K ^a   Amon, Lynn M ^a   Xue, Jun ^a   Arnett, Heather A ^b   Chen, Guang ^b   Breen, Patricia ^c   Buckner, Jane H ^c   Molitor, Jerry A ^c   Elkon, Keith B ^a   Schwartz, Stephen M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMGEN INC   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 16; INTERLEUKIN 1ALPHA; MESSENGER RNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMA PROTEIN; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; INFLAMMATION; LYMPHOCYTE; MONOCYTE; PRIORITY JOURNAL; SCLERODERMA; UPREGULATION;

ADULT; AGED; BLOOD PROTEINS; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; MONOCYTES; RNA, MESSENGER; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED;

EID: 43949127736     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23451     Document Type: Article

References (49)

1. Denton CP, Black CM. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90.
2. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
3. Ye S, Pang H, Gu YY, Hua J, Chen XG, Bao CD, et al. Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. Rheumatology (Oxford) 2003;42:1155-63.
4. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum 2007;56:1010-20.
5. Wiktor-Jedrzejczak W, Gordon S. Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor-1-deficient op/op mouse. Physiol Rev 1996;76:927-47.
6. Van Furth R, Diesselhoff-den Dulk MC, Mattie H. Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction. J Exp Med 1973;138:1314-30.
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
8. Irizarry RA, Gautier L, Cope LM. An R package for oligonucleotide array statistical analysis. In: Parmigiani G, Garrett ES, Irizarry RA, Zeger SL, editors. The analysis of gene expression data: methods and software. New York: Springer-Verlag; 2003. p. 102-18.
9. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article 3.
10. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
11. Beissbarth T, Speed TP. GOstat: find statistically overrepresented gene ontologies within a group of genes. Bioinformatics 2004;20:1464-5.
12. Komminoth P. Detection of mRNA in tissue sections using DIG-labeled RNA and oligonucleotide probes. In: Non-radioactive in situ hybridization application manual. 2nd ed. Mannheim: Boehringer; 1996. p. 126-35.
13. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998;95:15623-8.
14. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-5.
15. Stroncek DF, Basil C, Nagorsen D, Deola S, Arico E, Smith K, et al. Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J Transl Med 2005;3:24.
16. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003;4:177-86.
17. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
18. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78.
19. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007. E-pub ahead of print.
20. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006;45:694-702.
21. Gobl AE, Funa K, Alm GV. Different induction patterns of mRNA for IFN-α and -β in human mononuclear leukocytes after in vitro stimulation with herpes simplex virus-infected fibroblasts and Sendai virus. J Immunol 1988;140:3605-9.
22. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005;52:865-76.
23. Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002;26:549-57.
24. Zhou X, Tan FK, Xiong M, Milewicz DM, Feghali CA, Fritzler MJ, et al. Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001;167:7126-33.
25. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998;91:393-9.
26. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy [review]. Arthritis Rheum 2000;43:1431-42.
27. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002;107:133-44.
28. Stewart TA. Neutralizing interferon α as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003;14:139-54.
29. Solans R, Bosch JA, Esteban I, Vilardell M. Systemic sclerosis developing in association with the use of interferon α therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004;22:625-8.
30. Beretta L, Caronni M, Vanoli M, Scorza R. Systemic sclerosis after interferon-α therapy for myeloproliferative disorders. Br J Dermatol 2002;147:385-6.
31. Tahara H, Kojima A, Hirokawa T, Oyama T, Naganuma A, Maruta S, et al. Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. Intern Med 2007;46:473-6.
32. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
33. Fitzgerald-Bocarsly P. Natural interferon-α producing cells: the plasmacytoid dendritic cells. Biotechniques 2002;Suppl: 16-20, 22, 24-49.
34. Facchetti F, Vermi W, Mason D, Colonna M. The plasmacytoid monocyte/interferon producing cells. Virchows Arch 2003;443:703-17.
35. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001;294:1540-3.
36. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.
37. Becvar R, Stork J, Pesakova V, Stanova A, Hulejova H, Rysova L, et al. Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005;1051:404-12.
38. Falanga V, Kruskal JB, Franks JJ. Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma). J Am Acad Dermatol 1991;25:771-5.
39. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94:482-4.
40. Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001;60:846-51.
41. Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995;33:973-8.
42. Susol E, Rands AL, Herrick A, McHugh N, Barrett JH, Ollier WE, et al. Association of markers for TGFβ3, TGFβ2 and TIMP1 with systemic sclerosis. Rheumatology (Oxford) 2000;39:1332-6.
43. Indelicato M, Chiarenza V, Libra M, Malaponte G, Bevelacqua V, Marchini M, et al. Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. J Clin Lab Anal 2006;20:173-6.
44. Kawaguchi Y. IL-1α gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clin Exp Immunol 1994;97:445-50.
45. Kawaguchi Y, Tochimoto A, Ichikawa N, Harigai M, Hara M, Kotake S, et al. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum 2003;48:186-92.
46. Hutyrova B, Lukac J, Bosak V, Buc M, du Bois R, Petrek M. Interleukin 1α single-nucleotide polymorphism associated with systemic sclerosis. J Rheumatol 2004;31:81-4.
47. Dinarello CA. Interleukin-1 family of ligands and receptors. In: Paul WE, editor. Fundamental immunology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2003. pp 775-800.
48. Elkon KB. IL-1α responds to necrotic cell death. Nat Med 2007;13:778-80.
49. Glass WG, Sarisky RT, Vecchio AM. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res 2006;26:511-20.